<DOC>
	<DOCNO>NCT01965327</DOCNO>
	<brief_summary>Friedreich ataxia ( FRDA ) progressive neurodegenerative disease child adult presently therapy . Recently , study report interferon gamma ( IFN-g ) could raise frataxin protein level cell line derive patient Friedreich ataxia mouse model Friedreich ataxia . The present study test whether IFN-g safe , tolerate potentially efficacious heterogeneous cohort child FRDA .</brief_summary>
	<brief_title>Interferon Gamma-1b Friedreich Ataxia ( FRDA )</brief_title>
	<detailed_description>Study Objectives : Primary : â€¢ To assess effect Interferon Gamma-1b ( IFN-g ) increase frataxin expression protein child FRDA . Secondary : - To assess effect IFN-g neurological outcome ( FARS , performance measure , hear ) subject FRDA . - To assess effectiveness IFN-g quality life subject FRDA . - To assess safety tolerability IFN-g currently approve dose FRDA population . Study Phases : Screening - During screening , subject assess inclusion exclusion criterion . Intervention - Subjects begin treatment baseline visit dose study medication increase maximum dose four week . The subject maintain maximum dose 8 week . After 12 week , treatment stop . Study medication administer via subcutaneous injection three time per week 12 week . Follow-up - Follow-up visit occur 7 28 day subject complete 12 week active treatment .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Subjects FRDA confirm genetic test 2 expanded Guanineadenineadenine repeat Females pregnant breast feeding , intend become pregnant . Females childbearing potential must use reliable method contraception must provide negative urine pregnancy test screen Stable dos medication , vitamins supplement 30 day prior study entry duration study Parent/guardian permission ( informed consent ) child assent Any unstable illness investigator 's opinion precludes participation study Use investigational product within 30 day prior enrollment Subjects history substance abuse Presence clinically significant cardiac disease History hypersensitivity IFNg E. coli derive product Presence severe renal disease hepatic disease Clinically significant abnormal White blood cell count , hemoglobin platelet count Any subject planning schedule surgical procedure study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Friedreich ataxia</keyword>
	<keyword>Interferon gamma-1b</keyword>
	<keyword>FRDA</keyword>
</DOC>